Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cruz-Fernandez, J.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cruz-Fernandez, J.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors

J.M. Cruz-Fernandez1

Department of Medicine (Cardiology), School of Medicine, University of Seville and Cardiology Service, Hospital Universitario Virgen de Macarena, 41071 Seville, Spain

1 Correspondence: JosÉ M. Cruz-Fernández, Avda. Repúbica Argentina 15, 5-A, 41011 Seville, Spain.
jmcruz{at}hmv.sas.cica.es

Abstract

Despite its widespread use and documented efficacy in the treatment of acute coronary syndromes, aspirin has some limitations and the search for more effective and safer alternatives continues. This article analyses some current aspects of the treatment of these syndromes with the cyclooxygenase inhibitor triflusal.

Triflusal inhibits platelet cyclooxygenase activity but does not interfere significantly with endothelial synthesis of prostacyclin via the cyclooxygen ase-2 pathway. This drug also increases nitric oxide synthesis by neutrophils, and decreases the activity of nuclear transcription factor NF-B more than aspirin does. Moreover, triflusal inactivates intraplatelet phosphodiesterase and potentiates the antiaggregant effect of cAMP and cGMP, since it interferes with the degradation of these compounds. These pharmacological differences make triflusal potentially more effective and safer than aspirin.

For unstable angina or non-Q-wave myocardial infarction, triflusal is as effective as aspirin. In a multicentre study of more than 2000 patients with acute myocardial infarction, triflusal was as effective as aspirin, and had a better safety profile, significantly decreasing (> 60%) the incidence of cerebrovascular accidents. The patients likely to benefit most from treatment with triflusal were those receiving fibrinolytic treatment, patients older than 65 years, and those receiving concomitant treatment with angiotensin-converting enzyme inhibitors.

Triflusal is currently a valid alternative to aspirin for unstable angina, and for acute myocardial infarction it is the only alternative drug shown to be as effective as aspirin but safer.

Key Words: Acute coronary syndromes • antiplatelet agents • aspirin • cyclooxygenase inhibitors • triflusal


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.